Visão geral da empresa
A clinical-stage biopharmaceutical entity, Instil Bio, Inc. is dedicated to the development of a proprietary pipeline of novel therapeutic agents designed for specific medical indications. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high level of scientific risk and reliance on successful clinical trial outcomes before commercialization. The total market capitalization stands at $57.92M, while the annual revenue is not available for the trailing twelve months, and the employee count is not disclosed in the provided data. These valuation and revenue figures indicate that the company is a small-cap entity with a market cap significantly below the thresholds of established large-cap pharmaceutical firms, suggesting it is in an early developmental stage where revenue generation is secondary to research and development expenditures.
Saúde financeira
The financial performance for the trailing twelve months shows revenue figures as not available, a net income of $-71,372,000, and an EBITDA of $-52,373,000. The substantial gap between the reported revenue (which is unavailable) and the significant net loss reveals a cost structure dominated by heavy research and development expenses typical of clinical-stage companies, where operating costs far exceed current income generation. The free cash flow is reported at $-133,371,000, indicating a negative cash burn rate that limits immediate financial flexibility and necessitates reliance on external capital sources to fund ongoing operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue figures are insufficient to calculate meaningful margins given the current operational phase. Regarding liquidity and leverage, the company holds $79.67M in cash against $84.92M in total debt, resulting in a debt-to-equity ratio of 70.52, which suggests a highly leveraged balance sheet where cash reserves are slightly insufficient to cover total liabilities without refinancing. The current ratio is 39.53, a figure that indicates an extremely high level of short-term liquidity relative to current liabilities, likely due to the significant cash holdings compared to the small scale of current obligations. Finally, the return on equity is -50.4% and the return on assets is -14.2%, metrics that reveal that management has not yet generated positive returns on shareholder equity or asset bases, reflecting the inherent losses associated with the biotechnology development lifecycle.
Avaliação de valorização
The trailing P/E ratio is not available due to negative earnings, while the forward P/E is -0.58, implying that the market is pricing in future earnings recovery or continued losses rather than current profitability. The price-to-book ratio stands at 0.51, indicating that the stock is trading below its book value, which suggests the market is discounting the company's assets significantly, a common valuation characteristic for clinical-stage biotechs with unproven pipelines. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and the EV/EBITDA of -1.21, further illustrate the challenges in applying traditional multiple-based valuation methods to a company with no positive cash earnings. The 52-week trading range has a high of $42.79 and a low of $5.67, meaning the current market price sits within this wide volatility band, reflecting the high uncertainty surrounding the company's future clinical outcomes. The beta value is 2.03, which explains that the stock price exhibits more than double the volatility of the broader market, making it a highly speculative investment sensitive to shifts in sector sentiment and interest rates.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of growth rates between top-line sales and bottom-line profitability. For non-dividend payers like Instil Bio, the company does not distribute dividends to shareholders, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources, including its limited cash reserves, into its research and development pipeline rather than returning capital to investors. The overall growth and income profile is characterized by a complete lack of current dividend income and measurable historical growth, relying entirely on the potential future value of the lead candidate AXN-2510/IMM2510 in Phase 1b/2 clinical trials.